Vismodegib治疗基底细胞癌后皮肤鳞状细胞癌风险
本研究为回顾性队列研究,纳入1675例患者,比较Vismodegib治疗局部晚期或转移性基底细胞癌与标准手术治疗原发性基底细胞癌后皮肤鳞状细胞癌的发生风险。结果显示Vismodegib使用与后续皮肤鳞状细胞癌风险增加无关(校正风险比0.57;95%CI 0.28-1.16)。年龄、性别、既往非黑素瘤皮肤癌史和每年就诊次数与皮肤鳞状细胞癌发生显著相关。
要点
- Vismodegib未增加后续皮肤鳞状细胞癌风险(校正HR 0.57,95%CI 0.28-1.16)。
- 年龄、性别、既往非黑素瘤皮肤癌史和每年就诊次数与皮肤鳞状细胞癌发生显著相关。
- 研究局限性为使用历史对照队列作为比较对象。
核心结论
- 与基底细胞癌标准手术治疗相比,Vismodegib治疗未与后续皮肤鳞状细胞癌风险增加相关。
研究设计与样本
- 回顾性队列研究,纳入1675例患者,比较Vismodegib临床试验患者与加州大学旧金山分校非黑素瘤皮肤癌队列中接受标准治疗的原发性基底细胞癌患者。
主要发现
- Vismodegib使用与后续皮肤鳞状细胞癌风险增加无关(校正风险比0.57;95%置信区间0.28-1.16)。
- 年龄、性别、既往非黑素瘤皮肤癌史和每年就诊次数与皮肤鳞状细胞癌发生显著相关。
关键数值与推荐
- 校正风险比0.57(95%置信区间0.28-1.16)。
临床怎么用
- 临床应用Vismodegib治疗基底细胞癌时,无需因担心皮肤鳞状细胞癌风险增加而改变治疗决策。
局限性
- 使用历史对照队列作为比较对象。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vismodegib is a first-in-class agent targeting the hedgehog signaling pathway for treatment of patients with locally advanced basal cell carcinoma (BCC) and metastatic BCC. There have been concerns about the development of squamous cell carcinoma (SCC) in patients treated with this drug. OBJECTIVE: We sought to determine whether treatment with vismodegib is associated with an increase in the risk of cutaneous SCC. METHODS: In this retrospective cohort study, patients treated with vismodegib as part of phase I and II clinical studies were compared with participants from the University of California, San Francisco, Nonmelanoma Skin Cancer Cohort who received standard therapy for primary BCC. In total, 1675 patients were included in the analysis, and the development of SCC after vismodegib exposure was assessed. RESULTS: The use of vismodegib was not associated with an increased risk of subsequent development of SCC (adjusted hazard ratio, 0.57; 95% confidence interval, 0.28-1.16). Covariates including age, sex, history of previous nonmelanoma skin cancer, and number of visits per year were significantly associated with the development of SCC. LIMITATIONS: A limitation of the study was that a historic control cohort was used as a comparator. CONCLUSIONS: Vismodegib was not associated with an increased risk of subsequent SCC when compared with standard surgical treatment of BCC.
引用
- Bhutani T, Abrouk M, Sima CS, et al. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. J Am Acad Dermatol. 2017. PMID: 28780365. doi:10.1016/j.jaad.2017.03.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。